=> file caplus
FILE 'CAPLUS' ENTERED AT 13:28:02 ON 10 MAR 2005

FILE COVERS 1907 - 10 Mar 2005 VOL 142 ISS 11
FILE LAST UPDATED: 9 Mar 2005 (20050309/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 105 SEA FILE=REGISTRY SSS FUL L1
L4 1152 SEA FILE=CAPLUS L3
L5 93 SEA FILE=CAPLUS L4 AND SODIUM
L6 7 SEA FILE=CAPLUS L5 AND SODIUM(W)SALT

=> d l6 1-7 fbib abs hitstr

L6 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:878382 CAPLUS
DN 141:350161
TI Preparation of azole compounds as PTP1B inhibitors
IN Ikemoto, Tomoyuki; Tanaka, Masahiro; Yuno, Takeo; Sakamoto, Johei; Nakanishi, Hiroyuki; Nakagawa, Yuichi; Ohta, Takeshi; Sakata, Shohei; Morinaga, Hisayo
PA Japan Tobacco Inc., Japan
SO PCT Int. Appl., 542 pp.
CODEN: PIXXD2
DT Patent

LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089918	A1	20041021	WO 2004-JP5119	20040409

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	JP 2003-105267	A	20030409
	JP 2003-157590	A	20030603

OS MARPAT 141:350161
GI



I



II

AB Title compds. I [V = N, CH; W = S, O; m = 0-2; R1, R2 = H, alkyl; X = NR4, etc.; R4 = H, alkyl; n = 0-4; p = 0, 1; L = CR20R21, etc.; R20 = H, alkyl, etc.; R21 = H, alkyl, etc.; R = CO2R19, etc.; R19 = H, alkyl; B = aryl, heteroaryl; R3 = H, halo, etc.; Y = O, etc.; s = 0, 1; A = (un)substituted alkylene with cycloalkyl; Z = cycloalkyl, etc.] were prepared For example, O-alkylation of 5-hydroxynicotinic acid Me ester with compound II [Q = Cl], e.g., prepared from 4-bromoacetylbenzoic acid in 5 steps, followed by saponification afforded compound II [3-carboxypyridin-5-yloxy] in 44.1% overall yield. In PTP1B (protein tyrosine phosphatase 1B) inhibition assays, the IC50 value of compound II [Q = 3-carboxypyridin-5-yloxy] was 0.28 μM. Compds. I are claimed useful for the treatment of obesity, diabetes, etc. Formulations

are given.

IT **155141-29-0**, Rosiglitazone maleate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicaments with; preparation of azole compds. as PTP1B inhibitors for treatment of obesity and diabetes)

RN 155141-29-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:610104 CAPLUS
DN 141:134092
TI Telmisartan-simvastatin combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases
IN Riedel, Axel; Sendra, Josep-Maria; Leiter, Josef M. E.; Kauschke, Stefan; Mark, Michael
PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. Kg
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004062729	A1	20040729	WO 2004-EP175		20040114
	WO 2004062729	C1	20041007			
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA					
				DE 2003-10301372	A	20030116
				DE 2003-10335027	A	20030731
	DE 10301372	A1	20040729	DE 2003-10301372		20030116
	DE 10335027	A1	20050217	DE 2003-10335027		20030731
	US 2004259925	A1	20041223	US 2004-757295		20040114
				DE 2003-10301371	A	20030116
				US 2003-446695P	P	20030211
				DE 2003-10335027	A	20030731
				US 2003-503317P	P	20030916
	WO 2005011680	A1	20050210	WO 2004-EP8326		20040724
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				DE 2003-10335027	A	20030731
				DE 2003-10346260	A	20031006
				DE 2003-10356815	A	20031205

PATENT FAMILY INFORMATION:

FAN	2004:605412					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10301372	A1	20040729	DE 2003-10301372	20030116
	WO 2004062729	A1	20040729	WO 2004-EP175	20040114
	WO 2004062729	C1	20041007		
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA				
				DE 2003-10301372 A	20030116
				DE 2003-10335027 A	20030731
	US 2005004193	A1	20050106	US 2004-757015	20040114
				DE 2003-10301372 A	20030116
				US 2003-446437P P	20030211
				DE 2003-10335027 A	20030731
				US 2003-503317P P	20030916

FAN 2004:606351

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004062557	A2	20040729	WO 2004-EP174	20040114
	WO 2004062557	A3	20040916		
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA				
				DE 2003-10301371 A	20030116
				DE 2003-10335027 A	20030731
	DE 10301371	A1	20040805	DE 2003-10301371	20030116
	DE 10335027	A1	20050217	DE 2003-10335027	20030731
	US 2004259925	A1	20041223	US 2004-757295	20040114
				DE 2003-10301371 A	20030116
				US 2003-446695P P	20030211
				DE 2003-10335027 A	20030731
				US 2003-503317P P	20030916
	WO 2005011680	A1	20050210	WO 2004-EP8326	20040724
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				DE 2003-10335027 A	20030731
				DE 2003-10346260 A	20031006
				DE 2003-10356815 A	20031205

AB The invention discloses a method for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases, achieved by the improvement of endothelial function and the protection of organs, tissues and vessels when indications require a blood pressure check and a lipid level check, especially in patients that have been diagnosed with type 2 diabetes mellitus or if prediabetes is suspected. The method is also used for preventing diabetes and prediabetes and for the treatment of metabolic syndrome and insulin resistance in patients with normal blood pressure.

The method involves the combined administration of effective quantities of telmisartan, or a polymorph or salt thereof, and simvastatin. The invention also discloses suitable pharmaceutical compns. containing telmisartan, or a polymorph or salt thereof, and simvastatin, as a combined preparation for simultaneous, sep., or sequential use in the prophylaxis or treatment of the above diseases. Preparation of the **sodium salt** of telmisartan is described.

IT **122320-73-4**, Rosiglitazone
RL: PAC (Pharmacological activity); BIOL (Biological study)
(telmisartan-simvastatin combination for prophylaxis and treatment of cardiovascular, cardiopulmonary, pulmonary, and renal diseases)

RN 122320-73-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L6 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:606351 CAPLUS

DN 141:134089

TI Telmisartan-atorvastatin combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases

IN Riedel, Axel; Sendra, Josep-Maria; Leiter, Josef M. E.; Kauschke, Stefan; Mark, Michael

PA Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim

Pharma GmbH & Co. Kg
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA German

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004062557	A2	20040729	WO 2004-EP174		20040114
	WO 2004062557	A3	20040916			
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA					
				DE 2003-10301371	A	20030116
				DE 2003-10335027	A	20030731
	DE 10301371	A1	20040805	DE 2003-10301371		20030116
	DE 10335027	A1	20050217	DE 2003-10335027		20030731
	US 2004259925	A1	20041223	US 2004-757295		20040114
				DE 2003-10301371	A	20030116
				US 2003-446695P	P	20030211
				DE 2003-10335027	A	20030731
				US 2003-503317P	P	20030916
	WO 2005011680	A1	20050210	WO 2004-EP8326		20040724
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				DE 2003-10335027	A	20030731
				DE 2003-10346260	A	20031006
				DE 2003-10356815	A	20031205

PATENT FAMILY INFORMATION:

FAN 2004:605412

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	DE 10301372	A1	20040729	DE 2003-10301372		20030116
	WO 2004062729	A1	20040729	WO 2004-EP175		20040114
	WO 2004062729	C1	20041007			
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA					
				DE 2003-10301372	A	20030116
				DE 2003-10335027	A	20030731
	US 2005004193	A1	20050106	US 2004-757015		20040114
				DE 2003-10301372	A	20030116
				US 2003-446437P	P	20030211
				DE 2003-10335027	A	20030731
				US 2003-503317P	P	20030916

FAN 2004:610104

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004062729	A1	20040729	WO 2004-EP175	20040114
WO 2004062729	C1	20041007		
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA				
			DE 2003-10301372	A 20030116
			DE 2003-10335027	A 20030731
DE 10301372	A1	20040729	DE 2003-10301372	20030116
DE 10335027	A1	20050217	DE 2003-10335027	20030731
US 2004259925	A1	20041223	US 2004-757295	20040114
			DE 2003-10301371	A 20030116
			US 2003-446695P	P 20030211
			DE 2003-10335027	A 20030731
			US 2003-503317P	P 20030916
WO 2005011680	A1	20050210	WO 2004-EP8326	20040724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			DE 2003-10335027	A 20030731
			DE 2003-10346260	A 20031006
			DE 2003-10356815	A 20031205

AB The invention discloses a method for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary, or renal diseases, achieved by the improvement of endothelial function and the protection of organs, tissues and vessels when indications require a blood pressure check and a lipid level check, especially in patients that have been diagnosed with type 2 diabetes mellitus or if prediabetes is suspected. The method is also used for preventing diabetes and prediabetes and for the treatment of metabolic syndrome and insulin resistance in patients with normal blood pressure. The method involves the combined administration of effective amts. of telmisartan, or a polymorph or salt thereof, and atorvastatin. The invention also discloses suitable pharmaceutical compns. containing telmisartan, or a polymorph or salt thereof, and atorvastatin, as a combined preparation for simultaneous, sep. or sequential use in the prophylaxis or treatment of the above diseases. Preparation of the **sodium salt** of telmisartan is described.

IT **122320-73-4**, Rosiglitazone
RL: PAC (Pharmacological activity); BIOL (Biological study)
(telmisartan-atorvastatin combination for prophylaxis and treatment of cardiovascular, cardiopulmonary, pulmonary, and renal diseases)

RN 122320-73-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L6 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:182868 CAPLUS
DN 140:235595
TI Preparation of pyrrole based selective inhibitors of glycogen synthase kinase 3 for treating diabetes and other disorders
IN Desai, Manoj; Ni, Zhi-Jie; Ng, Simon; Pfister, Keith B.; Ramurthy, Savithri; Subramanian, Sharadha; Wagman, Allan S.
PA Chiron Corporation, USA
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018455	A1	20040304	WO 2003-US26625	20030821

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2002-405846P P 20020823
US 2004077707 A1 20040422 US 2003-646625 20030821
US 2002-405846P P 20020823

OS MARPAT 140:235595

GI



I



II

AB New pyrrole based compds. (shown as I; variables defined below; e.g. II), compns. and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compds. and compns. of the invention may be employed alone, or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer. For I: X is N, O, or (un)substituted C; W is absent or -O-, -S-, -S(O)-, -SO2-, -NH-, -NH-CO-, -NR'CO-, -NHSO2-, -NR'SO2-, -CO-, -CO2-, -CH2-, -CF2-, -CHF-, -CONH-, -CONR'-, and -NR'-, where R' is (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo; A1 is (un)substituted aryl or heteroaryl; R0 and R0' = H and Me. R1, R2, R3, and R4 = H, hydroxy, and (un)substituted loweralkyl, cycloloweralkyl, cyclicaminoalkyl, alkylaminoalkyl, loweralkoxy, amino, alkylamino, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, aryl and heteroaryl. R5 and R8 = H, halo, and (un)substituted loweralkyl, cycloalkyl, alkoxy, amino, aminoalkoxy, carbonyloxy, aminocarbonyloxy, alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cycloimido, heterocycloimido, amidino, cycloamidino, heterocycloamidino, guanidinyl, aryl, biaryl, heteroaryl, heteroarylaryl, heteroarylheteroaryl, heterocycloalkyl, heterocyclocarbonyloxy, heteroarylcarbonyloxy, and arylsulfonamido. R6 = H, and (un)substituted aryl, heteroaryl, and heterocyclo; R7 = H, hydroxy, halo, carboxy, nitro, amino, amido, amidino,

imido, cyano, sulfonyl, methanesulfonyl, and (un)substituted alkyl, alkoxy, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, alkylcarbonyloxy, arylcarbonyloxy, aralkylcarbonyloxy, etc.; addnl. details are given in the claims. Although the methods of preparation are not claimed, example prepns. and characterization data are included for hundreds of I. For example, II was prepared in 7 steps starting with esterification of (E)-3-(2,4-dichlorophenyl)-2-propenoic acid with tBuOH, followed by cyclization with p-tolylSO2CH2NC to give 4-(2,4-dichlorophenyl)pyrrole-3-carboxylic acid tert-Bu ester, followed by N-alkylation with 3-bromopropylphthalimide, followed by conversion of the phthalimide to the diamine with hydrazine, followed by N-substitution with (6-chloro-3-nitro-2-pyridyl)amine to give 1-[3-[(6-amino-5-nitropyridin-2-yl)amino]propyl]-4-(2,4-dichlorophenyl)pyrrole-3-carboxylic acid tert-Bu ester, followed by acid hydrolysis and carboxamide formation with (2S)-(+)-2-aminopropan-1-ol to give II. Representative I have GSK3 inhibitory activity <10 μM (specific compds. not mentioned); they exhibit a selectivity of ≥2-fold for GSK3 as compared to another kinase and more typically they exhibit a selectivity of ≥5-fold. Compds. I were shown to be capable of significantly reducing the potential of glutamate to induce neuronal cell death. In the glucose tolerance test, representative I exhibited good in vitro potency, and when formulated in captisol and administered s.c. to mice (30 mg/kg), exhibited high bioavailability and tissue penetrance in vivo. A significant reduction in basal hyperglycemia just prior to the glucose tolerance test, and significantly improved glucose disposal following glucose challenge were observed, comparable to the efficacy obtained with Troglitazone. Also of significance was the observation that insulin levels in treated animals remained lower than in control mice.

IT **122320-73-4**, Rosiglitazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug for diabetes; preparation of pyrrole based selective inhibitors of glycogen synthase kinase 3 for treating diabetes and other disorders)

RN 122320-73-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:256256 CAPLUS
DN 136:284397
TI **Sodium** salts of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
IN Craig, Andrew Simon; Millan, Michael
PA SmithKline Beecham P.L.C., UK
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002026735	A1	20020404	WO 2001-GB4334	20010928

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				GB 2000-23971	A	20000929
CA 2423975		AA	20020404	CA 2001-2423975		20010928
				GB 2000-23971	A	20000929
				WO 2001-GB4334	W	20010928
AU 2001092028		A5	20020408	AU 2001-92028		20010928
				GB 2000-23971	A	20000929
				WO 2001-GB4334	W	20010928
EP 1332142		A1	20030806	EP 2001-972248		20010928

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

				GB 2000-23971	A	20000929
				WO 2001-GB4334	W	20010928
BR 2001014308		A	20031014	BR 2001-14308		20010928
				GB 2000-23971	A	20000929
				WO 2001-GB4334	W	20010928
JP 2004509959		T2	20040402	JP 2002-531119		20010928
				GB 2000-23971	A	20000929
				WO 2001-GB4334	W	20010928
NZ 524933		A	20041224	NZ 2001-524933		20010928
				GB 2000-23971	A	20000929
				WO 2001-GB4334	A	20010928
BG 107679		A	20031231	BG 2003-107679		20030326
				GB 2000-23971	A	20000929
				WO 2001-GB4334	W	20010928
NO 2003001435		A	20030527	NO 2003-1435		20030328
				GB 2000-23971	A	20000929
				WO 2001-GB4334	W	20010928
ZA 2003002439		A	20040428	ZA 2003-2439		20030328
				GB 2000-23971	A	20000929
US 2004014752		A1	20040122	US 2003-381496		20030715
				GB 2000-23971	A	20000929
				WO 2001-GB4334	W	20010928
US 2004214866		A1	20041028	US 2004-849603		20040518
				GB 2000-23971	A	20000929
				WO 2001-GB4334	W	20010928
				US 2003-381496	B1	20030715

AB A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione **sodium salt** (I), or a pharmaceutically acceptable solvate thereof, characterized in that the **sodium salt** is non-hygroscopic or slightly hygroscopic; a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

Sodium hydroxide solution was reacted with 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and heated at 50°, then the solvent was separated to give I as crystalline solid.

IT **122320-73-4**

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazolidinedione **sodium salt** as antidabetic agent)

RN 122320-73-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **316371-83-2P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolidinedione **sodium salt** as antidabetic agent)

RN 316371-83-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:453060 CAPLUS
DN 135:46176
TI Preparation of antidiabetic and antihypertensive rosiglitazone Group IA and Group IIA metal salts and rosiglitazone-acid addition salt crystallization purification
IN Fischer, Janos; Fodor, Tamas; Levai, Sandor; Ballo, Ildiko; Petenyi, Endrene
PA Richter Gedeon Vegyeszeti Gyar Rt., Hung.
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001044240	A1	20010621	WO 2000-HU129	20001214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			HU 1999-4634	A	19991218
EP 1242418	A1	20020925	EP 2000-985704		20001214
EP 1242418	B1	20041027			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			HU 1999-4634	A	19991218
			WO 2000-HU129	W	20001214
EP 1475378	A1	20041110	EP 2004-13362		20001214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR					
			HU 1999-4634	A	19991218
			EP 2000-985704	A3	20001214
AT 280767	E	20041115	AT 2000-985704		20001214
			HU 1999-4634	A	19991218
			WO 2000-HU129	W	20001214

OS CASREACT 135:46176; MARPAT 135:46176

GI



I



II

AB Rosiglitazone, prepared by the condensation of 2-chloropyridine with MeNHCH2CH2OH, followed by etherification of the intermediate with 4-FC6H4CHO and condensation with 2,4-thiazolidinedione, was converted into its salts with CF3CO2H, HCl, TsOH, or HCO2H (I; HY is an acid with a pKa of <4) (e.g., rosiglitazone trifluoroacetate) which salts enable facile crystallization purification, on an industrial scale, in high yield, are hydrogenated back into rosiglitazone, and can be converted into rosiglitazone Group IA and IIA salts (II; X = Group IA metal, Group IIA metal) (e.g., rosiglitazone potassium salt; m.p. 203-205°), useful for the treatment of type-2 diabetes (no data), hypertension (no data), and eating disorders (no data), by treatment of rosiglitazone with metal bases (e.g, potassium hydroxide). A tablet formulation of rosiglitazone potassium salt is presented.

IT **122320-73-4P**, Rosiglitazone

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(in the preparation of antidiabetic and antihypertensive rosiglitazone Group IA and Group IIA metal salts and rosiglitazone-acid addition salt crystallization
purification)

RN 122320-73-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **316371-84-3P**, 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, potassium salt
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of antidiabetic and antihypertensive rosiglitazone Group IA and Group IIA metal salts and rosiglitazone-acid addition salt crystallization purification)

RN 316371-84-3 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, potassium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● K

IT **316371-83-2P**, 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, **sodium salt**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of antidiabetic and antihypertensive rosiglitazone Group IA and Group IIA metal salts and rosiglitazone-acid addition salt crystallization purification)

RN 316371-83-2 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2000:725436 CAPLUS
DN 133:301171
TI Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
IN Chen, Feng-jing; Patel, Manesh V.
PA Lipocine, Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059475	A1	20001012	WO 2000-US7342	20000316

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,

IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			US 1999-287043	A	19990406
US 6383471	B1	20020507	US 1999-287043		19990406
CA 2366702	AA	20001012	CA 2000-2366702		20000316
			US 1999-287043	A	19990406
			WO 2000-US7342	W	20000316
EP 1165048	A1	20020102	EP 2000-916547		20000316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
			US 1999-287043	A	19990406
			WO 2000-US7342	W	20000316

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025, Tween-20 0.3, Arlacel 186 0.2, **sodium** taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated gastric fluid.

IT **122320-73-4**, Rosiglitazone
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing hydrophobic therapeutic agents and carriers containing ionizing agents and surfactants and triglycerides)

RN 122320-73-4 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall
FILE 'USPATFULL' ENTERED AT 13:29:11 ON 10 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:29:11 ON 10 MAR 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 105 SEA FILE=REGISTRY SSS FUL L1
L7 39 SEA L3 AND SODIUM(W) SALT

=> d l7 1-39 ibib abs hitstr

L7 ANSWER 1 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2005:23978 USPATFULL
TITLE: Spinster-like protein genes, expression products, non-human animal model: uses in human metabolic disorders
INVENTOR(S): Peters, Thomas, Martinsried, GERMANY, FEDERAL REPUBLIC OF
Schluter, Volker, Martinsried, GERMANY, FEDERAL REPUBLIC OF
Grosse, Johannes, Martinsried, GERMANY, FEDERAL REPUBLIC OF
Schauerte, Heike, Martinsried, GERMANY, FEDERAL REPUBLIC OF
Marquardt, Andreas, Martinsried, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005020527	A1	20050127	
APPLICATION INFO.:	US 2004-818939	A1	20040405	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-460310P	20030404	(60)
	US 2004-538831P	20040123	(60)
	US 2004-550192P	20040304	(60)
	US 2004-550800P	20040305	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
NUMBER OF CLAIMS: 159
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 32 Drawing Page(s)
LINE COUNT: 6923
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a non-human vertebrate animal model displaying an alteration in fat metabolism or in the sensitivity towards

leptin or insulin, which model bears a mutation in the gene encoding the spinster like 1 protein (Spinl1). The invention also relates to mutant Spinl1 proteins and nucleic acid sequences encoding these proteins. Furthermore, the invention relates to the use of the non-human vertebrate animal model for the identification of diagnostic markers, or as a model for studying the molecular and physiological mechanisms associated with an alteration in fat metabolism or an alteration in the sensitivity towards leptin or insulin, or for the identification and testing of agents useful in the prevention, amelioration, or treatment of the above conditions. Agents, pharmaceutical compositions, and methods for treating the above conditions are likewise described, as are methods for identifying said agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(combination therapy; vertebrate Spinl (spinster-like protein) genes and proteins, non-human animal model bearing defective Spinl, and uses in metabolic disorder markers identifying and drug screening)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



ACCESSION NUMBER: 2004:334303 USPATFULL
TITLE: Anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma
INVENTOR(S): Shanghvi, Dilip S., Mumbai, INDIA
Mungre, Ashish P., Mumbai, INDIA
Zala, Yashoraj R., Mumbai, INDIA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004265381	A1	20041230	
APPLICATION INFO.:	US 2004-492070	A1	20040407	(10)
	WO 2002-IN203		20021008	

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2001-9842001	20011008
	WO 2002-IN107	20020409

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TIMOTHY J MARTIN, PC, 9250 W 5TH AVENUE, SUITE 200, LAKEWOOD, CO, 80226
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 797
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Asthma is defined as a chronic inflammatory disorder of the airways of the respiratory organ. It is characterized by reversible airflow obstruction causing cough, wheeze, chest lightness and shortness of breath. The inflammation of bronchial wall together with increased eosinophilis and other inflammatory products of the mast cells and lymphocytes further induce the hyper responsiveness of the bronchi so that it in turn, narrows more rapidly in response to a wide range of stimuli. Asmakure the anti-asthma drug has properties with proven pharmacological use for alleviating comman cold and persistent cough and finally building up of immunity against recurrence of asthma. One of the ingredients Adhatoda Vasica Nees (Basak) has a definite expectorant action. In acute bronchitis, it is found to afford immediate relief especially when the sputum is thick and tenacious. The depression of the Vagal terminals further relieves irritation and spasm of the bronchioles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **155141-29-0**, Rosiglitazone maleate
(oral spaced delivery system for biguanide and sulfonylurea antidiabetics)
RN 155141-29-0 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L7 ANSWER 3 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2004:328123 USPATFULL
TITLE: Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
INVENTOR(S): Tontonoz, Peter, Sherman Oaks, CA, UNITED STATES
Joseph, Sean B., San Diego, CA, UNITED STATES
Castrillo, Antonio, Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004259948	A1	20041223
APPLICATION INFO.:	US 2004-755720	A1	20040112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-439570P	20030110 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 1420
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is related to the role of liver X receptors (LXRs) in inflammation and immunity. More particularly, methods are disclosed for identifying and using LXR agonists for the treatment of inflammatory processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(reciprocal regulation of inflammation and lipid metabolism by liver x receptors)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L7 ANSWER 4 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:307783 USPATFULL			
TITLE:	Method for treating inflammatory diseases by administering a ppar-delta agonist			
INVENTOR(S):	Forrest, Michael J, Shrewsbury, NJ, UNITED STATES Berger, Joel P, Hoboken, NJ, UNITED STATES Moller, David E, Bedminister, NJ, UNITED STATES Wright, Samuel, Westfield, NJ, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004242459	A1	20041202	
APPLICATION INFO.:	US 2003-480363	A1	20031209	(10)
	WO 2002-US20974		20020607	
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2001-297356P		20010611	(60)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907			
NUMBER OF CLAIMS:	24			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1068			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating, controlling, preventing or reducing the risk of contracting an inflammatory disease or condition in a mammalian patient, comprises the steps of (1) selecting a patient in need thereof, and (2) treating the patient with a therapeutically effective amount of a composition comprising a PPAR-δ agonist. Inflammatory diseases that may be treated by this method include but are not limited to rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, degenerative joint disease, one or more connective tissue diseases, ankylosing spondylitis, and bursitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**, Rosiglitazone
(PPAR-δ agonist for treating inflammatory disease, and use with other agents)

RN 122320-73-4 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 5 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:279908 USPATFULL
TITLE:	Sustained-release medicines
INVENTOR(S):	Kawamura, Ryu, Osaka-shi, JAPAN Kusumoto, Keiji, Mishima-gun, JAPAN Hoshino, Tetsuo, Toyono-gun, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004219208	A1	20041104	
APPLICATION INFO.:	US 2004-485441	A1	20040202	(10)
	WO 2002-JP7862		20020801	

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2001-236794	20010803

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS:	45
EXEMPLARY CLAIM:	1
LINE COUNT:	4262

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sustained-release medicines comprising (A) an angiotensin II antagonist combined with (B) one or more drugs selected from among remedies for hypertension, hypoglycemics, remedies for hyperlipemia, antithromboties, remedies for menopause and anticancer drugs. Using these medicines, remarkably excellent effects can be achieved compared with the case of using each active ingredient alone, which makes it possible to lessen the administration dose and relieve side effects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **155141-29-0**, Rosiglitazone maleate
(sustained-release medicines containing angiotensin II antagonists in combination with other drugs for synergism)

RN 155141-29-0 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L7 ANSWER 6 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:274364 USPATFULL
TITLE:	Sodium salts of 5-'4-'2-(N-methyl-N-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione
INVENTOR(S):	Craig, Andrew Simon, Harlow, UNITED KINGDOM Millan, Michael, Harlow, UNITED KINGDOM
PATENT ASSIGNEE(S):	SmithKline Beecham p.l.c. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004214866	A1	20041028
APPLICATION INFO.:	US 2004-849603	A1	20040518 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2003-381496, filed on 15 Jul 2003, ABANDONED A 371 of International Ser. No. WO 2001-GB4334, filed on 28 Sep 2001, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-23971	20000929

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939
NUMBER OF CLAIMS:	13
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	4 Drawing Page(s)
LINE COUNT:	535

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione **sodium salt**, or a pharmaceutically acceptable solvate thereof, characterised in that the **sodium salt** is non-hygroscopic or slightly hygroscapic; a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**
(preparation of thiazolidinedione sodium salt as antidabetic agent)

RN 122320-73-4 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **316371-83-2P**
(preparation of thiazolidinedione sodium salt as antidabetic agent)
RN 316371-83-2 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

L7 ANSWER 7 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:216069 USPATFULL
TITLE:	Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
INVENTOR(S):	Erion, Mark D., Del Mar, CA, UNITED STATES van Poelje, Paul D., La Jolla, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004167178	A1	20040826
APPLICATION INFO.:	US 2004-780948	A1	20040217 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-470649, filed on 22 Dec 1999, GRANTED, Pat. No. US 6756360		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-114718P	19981224 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION

LEGAL REPRESENTATIVE: PAUL, HASTINGS, JANOFSKY & WALKER LLP, P.O. BOX 919092, SAN DIEGO, CA, 92191-9092
NUMBER OF CLAIMS: 141
EXEMPLARY CLAIM: 1
LINE COUNT: 11114
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, BRL 49653
(fructose-1,6-bisphosphatase inhibitor-insulin sensitizer combination for diabetes treatment, and inhibitor preparation)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 8 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2004:203011 USPATFULL
TITLE: Time pulsed release composition

10/849,603

INVENTOR(S): Shanghvi, Dilip Shantilal, Mumbai, INDIA
Dharmadhikari, Nitin Bhalachandra, Mumbai, INDIA
Zala, Yashoraj Rupsinh, Mumbai, INDIA
Khanna, Satish C., Basle, SWITZERLAND

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004156900	A1	20040812	
APPLICATION INFO.:	US 2003-474360	A1	20031009	(10)
	WO 2002-IN107		20020409	

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2001-3252001	20010410

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Westerman Hattori, Daniels & Adrian, PO Box 33275, Washington, DC, 20033-3275
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 762

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a timed pulse release composition comprising: a. a core composition comprising a therapeutically active agent, a swelling agent, and optionally water soluble compound(s) for inducing osmosis, and b. a coat composition comprising one or more film forming polymers, wherein upon imbibing fluid from the surrounding the core swells, and the coat ruptures to release in a pulse, the therapeutically active agent in a reliable manner at about a predetermined time wherein the reliable manner of rupture comprises rupturing of 36 tablets out of a total of 36 tablets at about the predetermined time when tested by subjecting the tablets to USP dissolution test using an aqueous media at 37±0.5oC, in a USP Type I or Type II apparatus at an rpm selected from the range of about 50 rpm to about 100 rpm.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **155141-29-0**, Rosiglitazone maleate
(oral spaced delivery system for biguanide and sulfonylurea antidiabetics)

RN 155141-29-0 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L7 ANSWER 9 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2004:161323 USPATFULL
TITLE: Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
INVENTOR(S): Erion, Mark D., Del Mar, CA, United States
van Poelje, Paul D., La Jolla, CA, United States
PATENT ASSIGNEE(S): Metabasis Therapeutics, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6756360	B1	20040629
APPLICATION INFO.:	US 1999-470649		19991222 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-114718P	19981223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Wilson, James O.
ASSISTANT EXAMINER: Lewis, Patrick
LEGAL REPRESENTATIVE: Paul Hastings Janofsky & Walker
NUMBER OF CLAIMS: 74
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 10051
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**, BRL 49653
(preparation of 2-(5-phosphono)furanyl substituted thiazoles as fructose-1,6-bisphosphatase inhibitors for use in combination with insulin sensitizer for treating diabetes)

RN 122320-73-4 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L7 ANSWER 10 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:139473 USPATFULL		
TITLE:	Agent for improving acidosis		
INVENTOR(S):	Odaka, Hiroyuki, Kobe-shi, JAPAN Suzuki, Masami, Osaka, JAPAN		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004106649	A1	20040603
APPLICATION INFO.:	US 2003-717738	A1	20031120 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-937447, filed on 26 Sep 2001, GRANTED, Pat. No. US 6677363 A 371 of International Ser. No. WO 2000-JP2413, filed on 13 Apr 2000, UNKNOWN		
	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1999-107119	19990414	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1513		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An agent for improving ketosis which comprises an insulin sensitizer, which has an excellent action and low toxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**, Rosiglitazone
(insulin sensitizers for improving ketosis, acidosis, and other conditions)

RN 122320-73-4 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 11 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:121157 USPATFULL
TITLE:	HMG-CoA reductase inhibitors and method
INVENTOR(S):	Robl, Jeffrey A., Newtown, PA, UNITED STATES Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES Sun, Chong-Qing, East Windsor, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004092573	A1	20040513
	US 6812345	B2	20041102
APPLICATION INFO.:	US 2003-602752	A1	20030624 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-875155, filed on 6 Jun 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-211595P	20000615 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS:	49

EXEMPLARY CLAIM: 1
LINE COUNT: 2545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis ##STR1##

and pharmaceutically acceptable salts thereof,

wherein X is O, S, SO, SO.sub.2 or NR.sub.7; ##STR2##

n is 0 or 1;

R.sub.1 and R.sub.2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; and

R.sub.3 to R.sub.10 are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**, Rosiglitazone
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 122320-73-4 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L7 ANSWER 12 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:113723 USPATFULL			
TITLE:	Spaced drug delivery system			
INVENTOR(S):	Shanghvi, Dilip Shantilal, Mumbai, INDIA Ganorkar, Kirti Wardhaman, Mumbai, INDIA Zala, Yashoraj Rupsinh, Mumbai, INDIA Dharmadhikari, Nitin Bhalachandra, Mumbai, INDIA Khanna, Satish C., Bottmingen, SWITZERLAND			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004086562	A1	20040506	
APPLICATION INFO.:	US 2003-466036	A1	20031117	(10)
	WO 2002-IN5		20020111	
	NUMBER		DATE	
PRIORITY INFORMATION:	IN 2001-372001		20010112	
	IN 2001-3232001		20010410	
	IN 2001-3242001		20010410	
	IN 2001-3252001		20010410	
	IN 2001-3262001		20010410	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903			
NUMBER OF CLAIMS:	31			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1756			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides to a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system, wherein the time of release of the two or more therapeutically active agents is designed to provide desired control on the disease condition. The present invention also provides a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system at a specified time prior to food intake by the patient. The present invention further provides a spaced drug delivery system that releases two or more antidiabetic agents at different times after oral administration, for the treatment of diabetes mellitus or conditions associated with diabetes mellitus. More particularly, the present invention provides a spaced drug delivery system that immediately releases one or more antidiabetic agents after oral administration of the system, and releases as a pulse one or more antidiabetic agents in a reliable manner at about a predetermined time after oral administration of the system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **155141-29-0**, Rosiglitazone maleate
(oral spaced delivery system for biguanide and sulfonylurea antidiabetics)

RN 155141-29-0 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L7 ANSWER 13 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2004:95420 USPATFULL
TITLE: Use of parathyroid hormone-related protein (PTHrP) in the diagnosis and treatment of chronic lung disease and other pathologies
INVENTOR(S): Torday, J. S., Rodondo Beach, CA, UNITED STATES
Rehan, Virender K., Torrance, CA, UNITED STATES
PATENT ASSIGNEE(S): Harbor/UCLA Research and Education Institute (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004072875	A1	20040415	
APPLICATION INFO.:	US 2003-352768	A1	20030127	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-377665P	20020502 (60)
	US 2002-421615P	20021025 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C., P O BOX 458, ALAMEDA, CA, 94501
NUMBER OF CLAIMS: 87
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Page(s)
LINE COUNT: 4523
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention pertains to the discovery that Parathyroid Hormone-related Protein (PTHrP) can be detect and/or stage, and/or treat chronic lung diseases. In particular, it was discovered that PTHrP levels in broncho-alveolar lavage are indicative of lung "health" and "disease, and can be used to predict lung disease in patients at risk of chronic lung disease. Treatment with PTHrP can reverse damage associated with chronic lung disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone **122320-73-4D**, Rosiglitazone, analog **155141-29-0**, Avandia **622402-70-4**, Avandamet
(use of parathyroid hormone-related protein (PTHrP) and other PPARγ ligands in diagnosis and treatment of chronic lung disease and other hyperoxia-induced pathol.)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 155141-29-0 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



RN 622402-70-4 USPATFULL
CN Imidodicarbonimidic diamide, N,N-dimethyl-, monohydrochloride, mixt. with 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 1115-70-4
CMF C4 H11 N5 . Cl H



● HCl

CM 2

CRN 155141-29-0
CMF C18 H19 N3 O3 S . C4 H4 O4

CM 3

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 4

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L7 ANSWER 14 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:70746 USPATFULL
TITLE:	Medicinal compositions containing diuretic and insulin resistance-improving agent
INVENTOR(S):	Takaoka, Masaya, Iwata-gun, JAPAN Araki, Kazushi, Kamakura-shi, JAPAN Kanda, Shoichi, Tokyo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004053974	A1	20040318
APPLICATION INFO.:	US 2003-606632	A1	20030626 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2001-JP11296, filed on 21 Dec 2001, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-394424	20001226

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	FRISHAUF, HOLTZ, GOODMAN & CHICK, PC, 767 THIRD AVENUE, 25TH FLOOR, NEW YORK, NY, 10017-2023
NUMBER OF CLAIMS:	20
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Page(s)
LINE COUNT:	6070

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a pharmaceutical composition comprising an insulin sensitizer and a diuretic which can prevent or treat side effects such as edema, cardiac enlargement, body fluid retension or hydrothorax caused by administration of an insulin sensitizer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**, Rosiglitazone
(medicinal compns. containing diuretics and insulin resistance-improving agents)

RN 122320-73-4 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 15 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:31748 USPATFULL		
TITLE:	Drugs for diabetes		
INVENTOR(S):	Del Soldato, Piero, Monza Milano, ITALY		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004023890	A1	20040205	
APPLICATION INFO.:	US 2003-398511	A1	20030411	(10)
	WO 2001-EP11665		20011009	

	NUMBER	DATE
PRIORITY INFORMATION:	IT 2000-MI2201	20001012

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	ARENT FOX KINTNER PLOTKIN & KAHN, 1050 CONNECTICUT AVENUE, N.W., SUITE 400, WASHINGTON, DC, 20036
NUMBER OF CLAIMS:	17
EXEMPLARY CLAIM:	1
LINE COUNT:	1593

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Use for the diabetes treatment of compounds or salts thereof, having the

following general formula (I): A-(B).sub.b0--(C).sub.c0--NO.sub.2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking group wherein the precursor must meet the tests described in the application, C is a a bivalent linking group as defined in the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **403731-62-4DP**, Rosiglitazone nitrate, nitroxyl-containing derivs.
(drug candidates; preparation of antidiabetic agents comprising antiinflammatory or analgesic drugs, selected bivalent linkers, and nitrate esters)

RN 403731-62-4 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, mononitrate (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 7697-37-2

CMF H N O3



L7 ANSWER 16 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:19448 USPATFULL		
TITLE:	Sodium salts of 5-[4-]2-(n-methyl-N-(2-pyridyl) ethoxy]benzyl]thiazolidine-2,4-dione		
INVENTOR(S):	Craig, Andrew Simon, Harlow, UNITED KINGDOM Millan, Michael, Harlow, UNITED KINGDOM		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004014752	A1	20040122	
APPLICATION INFO.:	US 2003-381496	A1	20030715	(10)
	WO 2001-GB4334		20010928	

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-23971	20000929

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939
NUMBER OF CLAIMS:	14
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	4 Drawing Page(s)
LINE COUNT:	551

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione **sodium salt**, or a pharmaceutically acceptable solvate thereof, characterised in that the **sodium salt** is non-hygroscopic or slightly hygroscapic; a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**
(preparation of thiazolidinedione sodium salt as antidabetic agent)

RN 122320-73-4 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT **316371-83-2P**
(preparation of thiazolidinedione sodium salt as antidabetic agent)
RN 316371-83-2 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, sodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● Na

L7 ANSWER 17 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2004:9621 USPATFULL			
TITLE:	Agent for improving ketosis			
INVENTOR(S):	Odaka, Hiroyuki, Kobe, JAPAN Suzuki, Masami, Ikeda, JAPAN			
PATENT ASSIGNEE(S):	Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6677363	B1	20040113	
	WO 2000061127		20001019	
APPLICATION INFO.:	US 2001-937447		20010926	(9)
	WO 2000-JP2413		20000413	
	NUMBER		DATE	
PRIORITY INFORMATION:	JP 1999-107119		19990414	
DOCUMENT TYPE:	Utility			

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weddington, Kevin E.
LEGAL REPRESENTATIVE: Chao, Mark, Ramesh, Elaine M.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1558
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An agent for improving ketosis which comprises an insulin sensitizer, which has an excellent action and low toxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(insulin sensitizers for improving ketosis, acidosis, and other conditions)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 18 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2003:258442 USPATFULL
TITLE: Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor

10/849,603

INVENTOR(S): Lai, Ching-San, Carlsbad, CA, UNITED STATES
Vassilev, Vassil P., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Medinox, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181495	A1	20030925
APPLICATION INFO.:	US 2003-394794	A1	20030321 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-44096, filed on 11 Jan 2002, GRANTED, Pat. No. US 6596770 Division of Ser. No. US 2000-565665, filed on 5 May 2000, GRANTED, Pat. No. US 6589991 Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, GRANTED, Pat. No. US 6093743
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2591
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel combinations of dithiocarbamate disulfide dimers with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with a thiazolidinedione for the treatment of diabetes. In another embodiment, In another embodiment, invention combinations further comprise additional active agents such as, for example, metformin, insulin, sulfonylureas, and the like. In another embodiment, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(dithiocarbamate disulfide derivs., preparation, compns., and therapeutic use with other agents)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 19 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2003:232615 USPATFULL
TITLE:	Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
INVENTOR(S):	Gatlin, Marjorie Regan, Hoboken, NJ, UNITED STATES Ball, Michele Ann, Morris Plains, NJ, UNITED STATES Mannion, Richard Owen, Mount Arlington, NJ, UNITED STATES Karnachi, Anees Abdulquadar, Hillsborough, NJ, UNITED STATES Guitard, Christiane, Hagenheim, FRANCE Allison, Malcolm, Basel, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003162816	A1	20030828
APPLICATION INFO.:	US 2003-345908	A1	20030116 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-663264, filed on 15 Sep 2000, PENDING

	NUMBER	DATE

10/849,603

PRIORITY INFORMATION: GB 2000-21055 20000826
US 2000-304196P 20000407 (60)
US 2000-240918P 20000309 (60)
US 1999-240911P 19990917 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 2226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) ##STR1##

or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(pharmaceuticals containing nateglinide or repaglinide for treating diabetes or conditions associated with diabetes)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 20 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2003:201447 USPATFULL
TITLE:	Combinations comprising dipeptidylpeptidase-iv inhibitor
INVENTOR(S):	Balkan, Bork, Madison, CT, UNITED STATES Hughes, Thomas Edward, Somerville, NJ, UNITED STATES Holmes, David Grenville, Binningen, SWITZERLAND Villhauer, Edwin Bernard, Morristown, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003139434	A1	20030724	
APPLICATION INFO.:	US 2002-181169	A1	20021010	(10)
	WO 2001-EP590		20010119	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-9489234	20000121
	US 2000-9619262	20000719

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ,

07936-1080
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1581
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α.sub.2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(combinations comprising dipeptidylpeptidase-IV inhibitor)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L7 ANSWER 21 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2003:123367 USPATFULL
TITLE:	Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
INVENTOR(S):	Gatlin, Marjorie Regan, Hoboken, NJ, United States Ball, Michele Ann, Morris Plains, NJ, United States Mannion, Richard Owen, Mount Arlington, NJ, United States Karnachi, Anees Abdulquadar, Hillsborough, NJ, United States Guitard, Christiane, Hegenheim, FRANCE Allison, Malcolm, Basel, SWITZERLAND
PATENT ASSIGNEE(S):	Novartis AG, Basel, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6559188	B1	20030506	
APPLICATION INFO.:	US 2000-663264		20000915	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-304196P	20000407	(60)
	US 2000-240918P	20000309	(60)
	US 1999-242911P	19990917	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Weddington, Kevin E.
LEGAL REPRESENTATIVE:	Thallemer, John D.
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	2176

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) ##STR1##

or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and metformin for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of

such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(pharmaceuticals containing nateglinide or repaglinide for treating diabetes or conditions associated with diabetes)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 22 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2003:86880 USPATFULL
TITLE: Drug comprising combination
INVENTOR(S): Sugiyama, Yasuo, Kawanishi-shi,Hyogo, JAPAN
Odaka, Hiroyuki, Kobe-shi, Hyogo, JAPAN
Naruo, Ken-ichi, Sanda-shi,Hyogo, JAPAN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003060488	A1	20030327	
APPLICATION INFO.:	US 2002-203300	A1	20020809	(10)

WO 2001-JP880 20010208

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-38265	20000210

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A TNF-α inhibitor comprising an insulin sensitizer in combination with an HMG-CoA reductase inhibitor is useful as an agent for the prophylaxis or treatment of an inflammatory disease and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(TNF-α inhibitors containing combination of insulin resistance-ameliorating agents with HMG-CoA reductase inhibitors)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 23 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2002:186092 USPATFULL
TITLE: Active agent delivery systems and methods for protecting and administering active agents
INVENTOR(S): Piccariello, Thomas, Blacksburg, VA, UNITED STATES
Olon, Lawrence P., Bristol, TN, UNITED STATES
Kirk, Randal J., Radford, VA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002099013	A1	20020725	
APPLICATION INFO.:	US 2001-933708	A1	20010822	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-274622P	20010308	(60)
	US 2000-247621P	20001114	(60)
	US 2000-247620P	20001114	(60)
	US 2000-247595P	20001114	(60)
	US 2000-247594P	20001114	(60)
	US 2000-247635P	20001114	(60)
	US 2000-247634P	20001114	(60)
	US 2000-247606P	20001114	(60)
	US 2000-247607P	20001114	(60)
	US 2000-247608P	20001114	(60)
	US 2000-247609P	20001114	(60)
	US 2000-247610P	20001114	(60)
	US 2000-247611P	20001114	(60)
	US 2000-247702P	20001114	(60)
	US 2000-247701P	20001114	(60)
	US 2000-247700P	20001114	(60)
	US 2000-247699P	20001114	(60)
	US 2000-247698P	20001114	(60)
	US 2000-247807P	20001114	(60)
	US 2000-247833P	20001114	(60)
	US 2000-247832P	20001114	(60)
	US 2000-247927P	20001114	(60)
	US 2000-247926P	20001114	(60)
	US 2000-247930P	20001114	(60)
	US 2000-247929P	20001114	(60)
	US 2000-247928P	20001114	(60)
	US 2000-247797P	20001114	(60)
	US 2000-247805P	20001114	(60)
	US 2000-247804P	20001114	(60)
	US 2000-247803P	20001114	(60)
	US 2000-247802P	20001114	(60)
	US 2000-247801P	20001114	(60)
	US 2000-247800P	20001114	(60)
	US 2000-247799P	20001114	(60)
	US 2000-247798P	20001114	(60)
	US 2000-247561P	20001114	(60)
	US 2000-247560P	20001114	(60)
	US 2000-247559P	20001114	(60)
	US 2000-247558P	20001114	(60)
	US 2000-247556P	20001114	(60)
	US 2000-247612P	20001114	(60)
	US 2000-247613P	20001114	(60)
	US 2000-247614P	20001114	(60)
	US 2000-247615P	20001114	(60)
	US 2000-247616P	20001114	(60)

US 2000-247617P 20001114 (60)
US 2000-247633P 20001114 (60)
US 2000-247632P 20001114 (60)
US 2000-247631P 20001114 (60)
US 2000-247630P 20001114 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Robert M. Schulman, Esq., Hunton & Williams, Suite 1200, 1900 K Street, N.W., Washington, DC, 20006-1100
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2048

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition comprising a polypeptide and an active agent covalently attached to the polypeptide. Also provided is a method for delivery of an active agent to a patient comprising administering to the patient a composition comprising a polypeptide and an active agent covalently attached to the polypeptide. Also provided is a method for protecting an active agent from degradation comprising covalently attaching the active agent to a polypeptide. Also provided is a method for controlling release of an active agent from a composition comprising covalently attaching the active agent to the polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **155141-29-0**, Rosiglitazone maleate
(compns. comprising a polypeptide and an active agent)

RN 155141-29-0 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A





CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L7 ANSWER 24 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2002:179187 USPATFULL
TITLE: HMG-CoA reductase inhibitors and method
INVENTOR(S): Robl, Jeffrey A., Newtown, PA, UNITED STATES
Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES
Sun, Chong-Qing, East Windsor, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002094977	A1	20020718
	US 6627636	B2	20030930
APPLICATION INFO.:	US 2001-7407	A1	20011204 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-875155, filed on 6 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-211595P	20000615 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Stephen B. Davis, Bristol-Myers Squibb Company, Patent Department, P.O. Box 4000, Princeton, NJ, 08543-4000
NUMBER OF CLAIMS: 49
EXEMPLARY CLAIM: 1
LINE COUNT: 2539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis ##STR1##

and pharmaceutically acceptable salts thereof, wherein X is O, S, SO, SO.sub.2 or NR.sub.7;

Z is ##STR2##

n is 0 or 1;

R.sub.1 and R.sub.2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; and

R.sub.3 to R.sub.10 are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 25 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2002:165255 USPATFULL

10/849,603

TITLE: Pharmaceutical composition
INVENTOR(S): Odaka, Hiroyuki, Hyogo, JAPAN
Yamane, Masahiro, Osaka, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002086885	A1	20020704
APPLICATION INFO.:	US 2001-36208	A1	20011229 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-380059, filed on 25 Aug 1999, PATENTED A 371 of International Ser. No. WO 1999-JP3496, filed on 29 Jun 1999, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-183700	19980630

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 1160
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic, which is useful as an agent for preventing or treating diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone **155141-29-0**, Rosiglitazone maleate
(insulin sensitizer in combination with an anorectic for the treatment of diabetes)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 155141-29-0 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L7 ANSWER 26 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2002:165253 USPATFULL
TITLE: Apoptosis inhibitor
INVENTOR(S): Matsui, Junji, Osaka, JAPAN
Tarui, Naoki, Nara, JAPAN
Momose, Yu, Hyogo, JAPAN
Naruo, Ken-Ichi, Hyogo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002086883	A1	20020704
	US 6555565	B2	20030429
APPLICATION INFO.:	US 2002-47816	A1	20020115 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-519274, filed on 7 Mar 2000, PENDING Continuation of Ser. No. US 1999-272747, filed on 15 Mar 1999, PATENTED A 371 of International Ser. No. WO 1998-JP5178, filed on 18 Nov 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-317926	19971119

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TAKEDA PHARMACEUTICALS NORTH AMERICA, INC, INTELLECTUAL PROPERTY DEPARTMENT, 475 HALF DAY ROAD, SUITE 500, LINCOLNSHIRE, IL, 60069
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 850
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An apoptosis inhibitor which comprises a compound of the formula: ##STR1##

wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula: --CO--, --CH(OH)-- or --NR.sup.3-- where R.sup.3 represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R.sup.1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R.sup.1; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof, or a compound having an insulin sensitivity enhancing activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(apoptosis inhibitor compds.)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 27 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2002:129992 USPATFULL
TITLE:	Apoptosis inhibitor
INVENTOR(S):	Matsui, Junji, Suita, JAPAN Tarui, Naoki, Nara, JAPAN Momose, Yu, Takarazuka, JAPAN Naruo, Ken-ichi, Sanda, JAPAN
PATENT ASSIGNEE(S):	Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6399639	B1	20020604
APPLICATION INFO.:	US 2000-519274		20000307 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-272747, filed on 15 Mar 1999, now patented, Pat. No. US 6087384 Continuation of Ser. No. WO 1998-JP5178, filed on 18 Nov 1998

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-317926	19971119

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED

PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Chao, Mark, Ramesh, Elaine M.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 796
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB. An apoptosis inhibitor which comprises a compound of the formula: ##STR1##

wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula: --CO--, --CH(OH)-- or --NR.sup.3-- where R.sup.3 represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R.sup.1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R.sup.1; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof, or a compound having an insulin sensitivity enhancing activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(apoptosis inhibitor compds.)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L7 ANSWER 28 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2002:119913 USPATFULL
TITLE:	HMG-CoA reductase inhibitors and method
INVENTOR(S):	Robl, Jeffrey A., Newtown, PA, UNITED STATES Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES Sun, Chong-Qing, East Windsor, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002061901	A1	20020523
	US 6620821	B2	20030916
APPLICATION INFO.:	US 2001-8154	A1	20011204 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-875218, filed on 6 Jun 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-211594P	20000615 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS:	45
EXEMPLARY CLAIM:	1
LINE COUNT:	2458

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis ##STR1##

and pharmaceutically acceptable salts thereof, ##STR2##

n is 0 or 1;

x is 0, 1, 2, 3 or 4;

y is 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH.sub.2).sub.x and/or (CH.sub.2).sub.y together with additional carbons form a 3 to 7 membered spirocyclic ring;

R.sub.1 and R.sub.2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

R.sub.3 is H or lower alkyl;

R.sub.4 and R.sub.7 are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(therapeutic compns. also containing; preparation of fused pyridine derivs. as
HMG-CoA reductase inhibitors)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 29 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2002:45629 USPATFULL
TITLE:	Method for the treatment and prevention of hyperuricemia
INVENTOR(S):	Fujiwara, Toshihiko, Ebina, JAPAN Iwasaki, Koichi, Chiba, JAPAN Horikoshi, Hiroyoshi, Funabashi, JAPAN
PATENT ASSIGNEE(S):	Sankyo Company, Limited, Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6353009	B1	20020305

APPLICATION INFO.: US 1998-195031 19981118 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-323182	19971125

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman, Langer & Chick, P.C.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3333

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**
(insulin sensitivity enhancers for use in treatment and prevention of hyperuricemia)

RN 122320-73-4 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L7 ANSWER 30 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2001:226658 USPATFULL		
TITLE:	Pharmaceutical composition for the treatment of diabetes		
INVENTOR(S):	Odaka, Hiroyuki, Kobe, Japan Yamane, Masahiro, Suita, Japan		
PATENT ASSIGNEE(S):	Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6329403	B1	20011211
	WO 2000000195		20000106
APPLICATION INFO.:	US 1999-380059		19990825 (9)
	WO 1999-JP3496		19990629
			19990825 PCT 371 date
			19990825 PCT 102(e) date
	NUMBER		DATE
PRIORITY INFORMATION:	JP 1998-183700		19980630
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Cook, Rebecca		
LEGAL REPRESENTATIVE:	Chao, Mark, Ramesh, Elaine M.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1134		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition which comprises an insulin sensitizer in combination with an anorectic, which is useful as an agent for preventing or treating diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**, Rosiglitazone **155141-29-0**, Rosiglitazone maleate
(insulin sensitizer in combination with an anorectic for the treatment of diabetes)

RN 122320-73-4 USPATFULL

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 155141-29-0 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 122320-73-4
CMF C18 H19 N3 O3 S

PAGE 1-A



PAGE 2-A



CM 2

CRN 110-16-7
CMF C4 H4 O4
CDES 2:Z

Double bond geometry as shown.



L7 ANSWER 31 OF 39 USPATFULL on STN
ACCESSION NUMBER: 2000:168044 USPATFULL
TITLE: Treatment of arteriosclerosis and xanthoma
INVENTOR(S): Tsujita, Yoshio, Tokyo, Japan
Horikoshi, Hiroyoshi, Tokyo, Japan
Shiomi, Masashi, Kobe, Japan
Ito, Takashi, Kobe, Japan
PATENT ASSIGNEE(S): Sankyo Company, Limited, Tokyo, Japan (non-U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6159997		20001212
APPLICATION INFO.:	US 1998-61446		19980416 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-676090, filed on 2 Jul 1996, now patented, Pat. No. US 5798375		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-167291	19950703

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman, Langer & Chick, P.C.
NUMBER OF CLAIMS: 210
EXEMPLARY CLAIM: 1
LINE COUNT: 1910
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]ethoxy}benzyl)thiazolidine-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo[5,4-b]pyridin-2-ylmethoxy)benzyl}thiazolidine-2,4-dione or its hydrochloride, 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, 5-[4-(1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione and 5-[4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, BRL-49653
(synergistic composition containing insulin sensitizer and HMG-CoA reductase inhibitor for treatment of arteriosclerosis)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 32 OF 39 USPATFULL on STN

ACCESSION NUMBER:	2000:157420 USPATFULL
TITLE:	Method for preventing and for treating autoimmune disease
INVENTOR(S):	Fujiwara, Toshihiko, Ebina, Japan Kurakata, Shinichi, Yokohama, Japan Fujita, Takashi, Kashiwa, Japan Hosokawa, Tsunemichi, Kanagawa, Japan Fukushige, Junichiro, Funabashi, Japan Horikoshi, Hiroyoshi, Funabashi, Japan
PATENT ASSIGNEE(S):	Sankyo Company, Limited, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6150371		20001121
APPLICATION INFO.:	US 1998-201477		19981130 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1997-JP1827, filed on 29 May 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-138667	19960531

JP 1996-181850 19960711
JP 1996-319225 19961129
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Krass, Frederick
LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman, Langer & Chick, P.C.
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 2773
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for preventing or treating autoimmune diseases (excluding type I diabetes) by administering an insulin resistance improving substance as an active ingredient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, BRL 49653
(remedy for autoimmune diseases and insulin resistance)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



ACCESSION NUMBER: 1998:101666 USPATFULL
TITLE: Treatment of arteriosclerosis and xanthoma
INVENTOR(S): Tsujita, Yoshio, Tokyo, Japan
Horikoshi, Hiroyoshi, Kobe, Japan
Ito, Takashi, Kobe, Japan
PATENT ASSIGNEE(S): Sankyo Company, Limited, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5798375		19980825	
APPLICATION INFO.:	US 1996-676090		19960702	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-167291	19950703

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Frishauf, Holtz, Goodman, Langer & Chick, Esq.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
LINE COUNT: 1158
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A combination of one or more HMG-CoA reductase inhibitors (for example pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin or atorvastatin) with one or more insulin sensitizers (for example troglitazone, pioglitazone, englitazone, BRL-49653, 5-(4-{2-[1-(4-2'-pyridylphenyl)ethylideneaminooxy]-ethoxy}benzyl)thiazolidine-2,4-dione, 5-{4-(5-methoxy-3-methylimidazo[5,4-b]pyridin-2-yl-methoxy)benzyl}thiazolidine-2,4-dione or its hydrochloride, 5-[4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione, 5-[4-(1-methylbenzimidazol-2-ylmethoxy)benzyl]-thiazolidine-2,4-dione and 5-[4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy) benzyllthiazolidine-2,4-dione) exhibits a synergistic effect and is significantly better at preventing and/or treating arteriosclerosis and/or xanthoma than is either of the components of the combination alone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, BRL-49653
(synergistic composition containing insulin sensitizer and HMG-CoA reductase inhibitor for treatment of arteriosclerosis)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 34 OF 39 USPATFULL on STN

ACCESSION NUMBER:	96:120902 USPATFULL
TITLE:	Heterocyclic compounds and their use in the treatment of Type-II diabetes
INVENTOR(S):	Haigh, David, Horsham, England
PATENT ASSIGNEE(S):	SmithKline Beecham PLC, Brentford, England (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5589492		19961231	
	WO 9321166		19931028	
APPLICATION INFO.:	US 1994-318615		19941212	(8)
	WO 1993-GB735		19930407	
			19941212	PCT 371 date
			19941212	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-8016	19920410
	GB 1992-8451	19920416
	GB 1992-27046	19921229

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Northington-Davis, Zinna
LEGAL REPRESENTATIVE: Stein-Fernandez, Nora, King, William T., Lentz, Edward T.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 1827
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of the formula A.sup.1 --X--(CH.sub.2).sub.n --O--A.sup.2 --A.sup.3 --CO.R.sup.2 (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group; A.sup.2 represents a benzene ring having three optional substituents; A.sup.3 represents a moiety of formula --(CH.sub.2).sub.m --CHR.sup.1 -- wherein R.sup.1 represents a halogen atom or a moiety of formula S(O).sub.p A.sup.4 wherein A.sup.4 represents hydrogen, substituted or unsubstituted alkyl, aryl, aralkyl, alkylcarbonyl or an aromatic heterocyclyl group and p represents zero or an integer 1 or 2 and m represents zero or an integer in the range of from 1 to 5, or A.sup.3 represents a moiety of formula --CH.dbd.CR.sup.1 -- wherein R.sup.1 is as defined above; R.sup.2 represents OR.sup.3 wherein R.sup.3 represents hydrogen, alkyl, aryl or aralkyl, or R.sup.2 represents --NR.sup.4 R.sup.5 wherein R.sup.4 and R.sup.5 each independently represent hydrogen or alkyl or R.sup.4 and R.sup.5 together with the nitrogen atom to which they are attached form a heterocyclic ring; X represents O, S or NR wherein R represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; and n represents an integer in the range of from 2 to 6; a process for the preparation of such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound and composition in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**
(reactant for [[[(pyridyl)amino]alkoxy]phenyl]alkanoate antidiabetic)
RN 122320-73-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 35 OF 39 USPAT2 on STN

ACCESSION NUMBER:	2004:121157 USPAT2
TITLE:	HMG-CoA reductase inhibitors and method
INVENTOR(S):	Robl, Jeffrey A., Newtown, PA, United States Chen, Bang-Chi, Plainsboro, NJ, United States Sun, Chong-Qing, East Windsor, NJ, United States
PATENT ASSIGNEE(S):	Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6812345	B2	20041102
APPLICATION INFO.:	US 2003-602752		20030624 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-7407, filed on 4 Dec 2001, now patented, Pat. No. US 6627636 Continuation-in-part of Ser. No. US 2001-875155, filed on 6 Jun 2001, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-211595P	20000615 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED

PRIMARY EXAMINER: Huang, Evelyn Mei
LEGAL REPRESENTATIVE: Rodney, Burton
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis ##STR1##

and pharmaceutically acceptable salts thereof, wherein X is O, S, SO, SO.sub.2 or NR.sub.7;

Z is ##STR2##

n is 0 or 1;

R.sub.1 and R.sub.2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; and

R.sub.3 to R.sub.10 are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**, Rosiglitazone
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 122320-73-4 USPAT2

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L7 ANSWER 36 OF 39 USPAT2 on STN
ACCESSION NUMBER: 2003:214411 USPAT2
TITLE: Compounds
INVENTOR(S): Hindley, Richard Mark, Epsom, UNITED KINGDOM
PATENT ASSIGNEE(S): Beecham Group p.l.c., Brentford, UNITED KINGDOM (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6686475	B2	20040203
APPLICATION INFO.:	US 2002-71824		20020207 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-850965, filed on 8 May 2001, now abandoned Division of Ser. No. US 1994-358327, filed on 19 Dec 1994, now patented, Pat. No. US 6288095 Continuation of Ser. No. US 1993-53997, filed on 26 Apr 1993, now abandoned Continuation-in-part of Ser. No. US 1991-641474, filed on 15 Jan 1991, now patented, Pat. No. US 5232925 Continuation-in-part of Ser. No. US 1989-457272, filed on 27 Dec 1989, now patented, Pat. No. US 5002953 Continuation-in-part of Ser. No. US 1988-238764, filed on 30 Aug 1988, now abandoned Division of Ser. No. US 458033
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Sieburth, Kathryn L., McCarthy, Mary E., Kinzig, Charles M.
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1747
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula (I): ##STR1##

or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, wherein:

A.sup.1 represents a substituted or unsubstituted aromatic heterocyclyl group;

R.sup.1 represents a hydrocarbon atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;

R.sup.2 and R.sup.3 each represent hydrogen, or R.sup.2 and R.sup.3 together represent a bond;

A.sup.2 represents a benzene ring having a total up to five

substituents; and

n represents an integer in the range of from 2 to 6; pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4P**
(preparation of, as hypoglycemic and hypolipidemic)
RN 122320-73-4 USPAT2
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 37 OF 39 USPAT2 on STN
ACCESSION NUMBER: 2002:179187 USPAT2
TITLE: HMG-CoA reductase inhibitors and method
INVENTOR(S): Robl, Jeffrey A., Newtown, PA, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6627636	B2	20030930

APPLICATION INFO.: US 2001-7407 20011204 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-875155, filed on 6 Jun 2001, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-211595P	20000615 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Huang, Evelyn Mei
LEGAL REPRESENTATIVE: Rodney, Burton
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2356
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis ##STR1##

and pharmaceutically acceptable salts thereof, wherein X is O, S, SO, SO.sub.2 or NR.sub.7; Z is ##STR2##

n is 0 or 1; R.sub.1 and R.sub.2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; and R.sub.3 to R.sub.10 are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)
RN 122320-73-4 USPAT2
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L7 ANSWER 38 OF 39 USPAT2 on STN

ACCESSION NUMBER:	2002:165253 USPAT2
TITLE:	Apoptosis inhibitor
INVENTOR(S):	Matsui, Junji, Suita, JAPAN Tarui, Naoki, Nara, JAPAN Momose, Yu, Takarazuka, JAPAN Naruo, Ken-ichi, Sanda, JAPAN
PATENT ASSIGNEE(S):	Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6555565	B2	20030429
APPLICATION INFO.:	US 2002-47816		20020115 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-519274, filed on 7 Mar 2000, now patented, Pat. No. US 6399639, issued on 4 Jun 1982 Continuation of Ser. No. US 272747

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-317926	19971119
	WO 1998-JP5178	19981118

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Chao, Mark, Ramesh, Elaine M.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 819
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An apoptosis inhibitor which comprises a compound of the formula: ##STR1##

wherein R represents a hydrocarbon group that may be substituted or a heterocyclic group that may be substituted; Y represents a group of the formula: --CO--, --CH(OH)-- or --NR.sup.3-- where R.sup.3 represents an alkyl group that may be substituted; m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a chemical bond or a bivalent aliphatic hydrocarbon group having 1 to 7 carbon atoms; Q represents oxygen or sulfur; R.sup.1 represents hydrogen or an alkyl group; ring E may have further 1 to 4 substituents, which may form a ring in combination with R.sup.1; L and M respectively represent hydrogen or may be combined with each other to form a chemical bond; or a salt thereof, or a compound having an insulin sensitivity enhancing activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **122320-73-4**, Rosiglitazone
(apoptosis inhibitor compds.)

RN 122320-73-4 USPAT2

CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





L7 ANSWER 39 OF 39 USPAT2 on STN
ACCESSION NUMBER: 2002:119913 USPAT2
TITLE: HMG-CoA reductase inhibitors and method
INVENTOR(S): Robl, Jeffrey A., Newtown, PA, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6620821	B2	20030916
APPLICATION INFO.:	US 2001-8154		20011204 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-875218, filed on 6 Jun 2001, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-211594P	20000615 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Huang, Evelyn Mei
LEGAL REPRESENTATIVE: Rodney, Burton
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 2242
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis ##STR1##

and pharmaceutically acceptable salts thereof, ##STR2##

n is 0 or 1;

x is 0, 1, 2, 3 or 4;

y is 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH.sub.2).sub.x and/or (CH.sub.2).sub.y together with additional carbons form a 3 to 7 membered spirocyclic ring;

R.sub.1 and R.sub.2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl;

R.sub.3 is H or lower alkyl;

R.sub.4 and R.sub.7 are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **122320-73-4**, Rosiglitazone
(therapeutic compns. also containing; preparation of fused pyridine derivs. as
HMG-CoA reductase inhibitors)
RN 122320-73-4 USPAT2
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=>